MOLM-13

Name: MOLM-13
Brand: Procell
SKU: CL-0681
Price: 460.0 USD
Availability: InStock

Copy the product info.

Cat. No.: CL-0681

Publications(17)

CL-0681

$ 460.00

Select a size

1×10^6Cells/Vial×2Vials

Quantity

- +

In stock

Inquire

For order requirements and technical needs, please Contact Us

Product Introduction Documents Publications

Product Introduction

General information

Cell Name	MOLM-13
Synonyms	MOLM13;Molm13;Molm 13
Cellosaurus Accession	CVCL_2119
Organism	Human
Growth Properties	Suspension
Morphology	Lymphoblast-like
Disease	leukemia cells
Tissue	Peripheral blood
Age	20Y
Sex	Male

Handling information

Instructions	1. Check all containers for leakage or breakage. 2. Remove the frozen cells from the dry ice packaging and immediately transfer them to liquid nitrogen (liquid or vapor phase) for long-term cryopreservation.
Complete Medium	RPMI-1640 [PM150110]+10% Nutrient+1% Supplement
Incubation Atmosphere	Air, 95%; CO₂, 5%
Temperature	37℃
Subcultivation Ratio	1:2-1:6
Medium Renewal	2 to 3 times per week
Subculturing Procedure	Cultures can be maintained by either supplementing with fresh medium or exchanging medium via centrifugation. The recommended centrifugation conditions are 1200 rpm (approximately 250 × g) for 3 minutes.
Freeze Medium	90% FBS+10% DMSO
Storage Conditions	For long-term cryopreservation, cryovials should be stored in liquid nitrogen at −150°C to −196°C. Storage at −80°C is restricted to short-term interim use only.

Reference materials

Background

MOLM-13 was established from the peripheral blood of a 20-year-old man with acute myeloid leukemia AML FAB M5a at relapse in 1995 after initial myelodysplastic syndrome (MDS, refractory anemia with excess of blasts, RAEB); described to carry internal tandem duplication of FLT3; the FLT3 protein is not expressed; cell line carries the CBL deltaExon8 mutant; sister cell line of MOLM-14 (ACC 777). Exome and RNA sequence data are available (see Ref 18187 and Exome sequence and RNA-Seq).

Biosafety Level

BSL-1

Documents

MSDS

Publications

Synthesis of imidazopyridines via NaIO4/TBHP-promoted (3 + 2) cycloaddition and biological evaluation as anticancer agents

Journal: RSC Advances (2025) IF: 3.9

DOI: 10.1039/D5RA01949D

Product Cited: MOLM-13

Siglec6 CAR T cells suppressed progression of AML via inhibiting Siglec6 and SHP2 induced Src and ERK signaling activation

Journal: Scientific Reports (2025) IF: 3.8

DOI: 10.1038/s41598-025-00456-x

Product Cited: MOLM-13

Synergy Between second-generation FLT3 inhibitors and the ERK1/2 inhibitor Ulixertinib in FLT3-ITD-mutated acute myeloid leukemia (AML) cells

Journal: MEDICAL ONCOLOGY (2025) IF: 3.5

DOI: 10.1007/s12032-025-03054-z

Product Cited: MOLM-13 Cells Line, MV-4-11 Cells Line

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin

Journal: Journal for ImmunoTherapy of Cancer (2024) IF: 10.3

DOI: 10.1136/jitc-2024-008888

Product Cited: MOLM-13 Cells Line, 293T/17 Cells Line, IM95 Cells Line, Eca-109 Cells Line, MKN-45 Cells Line, NK-92 Cells Line

Activation of non-classical Wnt signaling pathway effectively enhances HLA-A presentation in acute myeloid leukemia

Journal: Frontiers in Oncology (2024) IF: 3.5

DOI: 10.3389/fonc.2024.1336106

Product Cited: THP-1 Cells Line, HL-60 Cells Line, Human Bone Marrow Hematopoietic Stem Cells, Human Bone Marrow Hematopoietic Stem Cell Complete Medium, MOLM-13 Cells Line